Development of Potent Inhibitors of Botulinum Neurotoxin Type B

Journal of Medicinal Chemistry

Volumn 46, Issue 22, 2003, Pages 4648-4656

  Anne, Christine ^a   Turcaud, Serge ^a   Quancard, Jean ^a   Teffo, Franck ^a   Meudal, Hervé ^a   Fournié Zaluski, Marie Claude ^a   Roques, Bernard P ^a  

^a Laboratoire de Pharmacochimie   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 (2 AMINO 3 SULFANYLPROPYL)BENZAMIDE; 4 (2 AMINO 3 SULFANYLPROPYL)BENZENESULFONAMIDE; 4 (2 AMINO 3 SULFANYLPROPYL)BENZENESULFONIC ACID; 4 [2 AMINO 3 [1 (1 BENZYLCARBAMOYL 2 METHYLCARBAMOYL) 2 BIPHENYL 4 YLETHYLCARBAMOYL] 3 SULFANYLPROPYL]BENZOIC ACID; 4 [2 AMINO 3 [1 (1 BENZYLCARBAMOYL 2 PHENYLETHYLCARBAMOYL) 2 (1 METHYL 1H INDOL 3 YL)ETHYLCARBAMOYL] 3 SULFANYLPROPYL]BENZOIC ACID; 4 [2 AMINO 3 [1 (1 BENZYLCARBAMOYL 2 PHENYLETHYLCARBAMOYL) 2 BIPHENYL 4 YLETHYLCARBAMOYL] 3 SULFANYLPROPYL]BENZOIC ACID; 4 [2 AMINO 3 [1 (1 BENZYLCARBAMOYL 2 PHENYLETHYLCARBAMOYL) 2 NAPHTHALEN 1 YL ETHYLCARBAMOYL] 3 SULFANYLPROPYL]BENZOIC ACID; 4 [2 AMINO 3 [1 (2 BENZO[B]THIOPHEN 3 YL 1 BENZYLCARBAMOYLETHYLCARBAMOYL) 2 BIPHENYL 4 YLETHYLCARBAMOYL] 3 SULFANYLPROPYL]BENZOIC ACID; 4 [2 AMINO 3 [1 (BENZYLCARBAMOYL 2 PHENYLETHYLCARBAMOYL) 2 (1H INDOL 3 YL)ETHYLCARBAMOYL] 3 SULFANYLPROPYL]BENZOIC ACID; 4 [2 AMINO 3 [1 [1 BENZYLCARBAMOYL 2 (3H IMIDAZOL 4 YL)ETHYLCARBAMOYL] 2 BIPHENYL 4 YLETHYLCARBAMOYL] 3 SULFANYLPROPYL]BENZOIC ACID; 4 [2 AMINO 3 [1 [1 BENZYLCARBAMOYL 2 (4 HYDROXYPHENYL)ETHYLCARBAMOYL] 2 BIPHENYL 4 YLETHYLCARBAMOYL] 3 SULFANYLPROPYL]BENZOIC ACID; BETA AMINO ACID; BETA AMINOTHIOL DERIVATIVE; BOTULINUM TOXIN B; METALLOPROTEINASE; NEUROTOXIN; PEPTIDE DERIVATIVE; PEPTIDE LIBRARY; PSEUDOTRIPEPTIDE; UNCLASSIFIED DRUG; ZINC METALLOPROTEINASE;

ARTICLE; BOTULISM; DRUG ACTIVITY; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG SYNTHESIS; MOLECULAR MODEL; PATHOGENESIS; STRUCTURE ACTIVITY RELATION;

EID: 0142124198     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0300680     Document Type: Article

References (46)

1. Simpson, L. L. The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol. Rev. 1981, 33, 155-188.
2. Middlebrook, J. L.; Brown, J. E. Immunodiagnosis and immunotherapy of tetanus and botulinum neurotoxins. Curr. Top. Microbiol. Immunol. 1995, 195, 89-122.
3. Shapiro, R. L.; Hatheway, C.; Swerdlow, D. L. Botulism in the United States: a clinical and epidemiologic review. Ann. Intern. Med. 1998, 129, 221-228.
4. Montecucco, C.; Papini, E.; Schiavo, G. Bacterial protein toxins penetrate cells via a four-step mechanism. FEBS Lett. 1994, 346, 92-98.
5. Schiavo, G.; Benfenati, F.; Poulain, B.; Rossetto, O.; Polverino de Laureto, P. DasGupta, B. R.; Montecucco, C. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 1992, 359, 832-835.
6. Humeau, Y.; Doussau, F.; Grant, N. J.; Poulain, B. How botulinum and tetanus neurotoxins block neurotransmitter release. Biochimie 2000, 82, 427-446.
7. Schiavo, G.; Matteoli, M.; Montecucco, L. Neurotoxins affecting neuroexocytosis. Physiol. Rev. 2000, 80, 717-766.
8. Matthews, B. W. Structural basis of the action of thermolysin and related zinc peptidases. Acc. Chem. Res. 1988, 21, 333-340.
9. Roques, B. P.; Noble, F.; Daugé, V.; Fournié-Zaluski, M. C.; Beaumont, A. Neutral endopeptidase 24.11. Structure, inhibition, and experimental and clinical pharmacology. Pharmacol. Rev. 1993, 45 (1), 87-146.
10. Hanson, M. A.; Stevens, R. C. Cocrystal structure of synaptobrevin-II bound to botulinum neurotoxin type B at 2.0 A resolution. Nat. Struct. Biol. 2000, 7, 687-692.
11. Arnon, S. S.; Schechter, R.; Inglesby, T. V.; Henderson, D. A.; Bartlett, J. G.; Ascher, M. S.; Eitzen, E.; Fine, A. D.; Hauer, J.; Layton, M.; Lillibridge, S.; Osterholm, M. T.; O'Toole, T.; Parker, G.; Perl, T. M.; Russell, P. K.; Swerdlow, D. L.; Tonat, K.; Working Group on Civilian Biodefense. Botulinum toxin as a biological weapon: Medical and public health management. JAMA 2001, 285, 1059-1070.
12. Scientific and Therapeutic Aspects of Botulinum Toxin; Brin, M. F., Hallett, M., Jankovic, J., Eds.; Lippincott Williams & Wilkins: Philadelphia, 2002; pp 189-371.
13. Borodic, G.; Johnson, E.; Goodnough, M.; Schautz, E. Botulinum toxin therapy, immunologic resistance and problems with available materials, Neurology 1996, 46, 26-29.
14. Söllner, T.; Bennett, M. K.; Whiteheart, S. W.; Scheller, R. H.; Rothman, J. E. A protein assembly disassembly pathway in vitro that may correspond to sequential steps of synaptic vesicle docking, activation, and fusion. Cell 1993, 75, 409-418.
15. Anne, C.; Cornille, F.; Lenoir, C.; Roques, B. P. High-throughput assay determination of botulinum type B neurotoxin protease activity. Anal. Biochem. 2001, 291, 253-261.
16. Martin, L.; Cornille, F.; Turcaud, S.; Meudal, H.; Roques, B. P.; Fournié-Zaluski, M. C. Metallopeptidase inhibitors of tetanus toxin: A combinatorial approach. J. Med. Chem. 1999, 42, 515-525.
17. Chauvel, E. N.; Llorens-Cortes, C.; Coric, P.; Wilk, S.; Roques, B. P.; Fournie-Zaluski, M.-C. Differential inhibition of aminopeptidase A and aminopeptidase N by new beta-amino thiols. J. Med. Chem. 1994, 37, 2950-2957.
18. Martin, L.; Cornille, F.; Coric, P.; Roques, B. P.; Fournié -Zaluski, M.-C. Beta-amino-thiols inhibit the zinc metallopeptidase activity of tetanus toxin light chain. J. Med. Chem. 1998, 41, 3450-3460.
19. Chauvel, E. N.; Coric, P.; Llorens Cortès, C.; Wilk, S.; Roques, B. P.; Fournié-Zaluski, M. C. Investigation of the active site of aminopeptidase A using a series of new thiol-containing inhibitors. J. Med. Chem. 1991, 37, 1339-1346.
20. David, C.; Bischoff, L.; Meudal, H.; Mothe, A.; DeMota, N.; Danascimento, C.; Llorens-Cortes, C.; Fournié-Zaluski, M. C.; Roques, B. P. Investigation of subsite preferences in aminopeptidase A (EC 3.4.11.7) led to the design of the first highly potent and selective inhibitors of this enzyme. J. Med. Chem. 1999, 42, 5197-5211.
21. Fournié-Zaluski, M. C.; Coric, P.; Turcaud, S.; Bruetschy, L.; Lucas, E.; Noble, F.; Roques, B. P. Potent and systemically active aminopeptidase N inhibitors designed from active-site investigation. J. Med. Chem. 1992, 35, 1259-1266.
22. Yaozhong, J.; Changyou, Z.; Skengde, W.; Daimo, L.; Yonan, M.; Guilar, L. Solid-liquid-phase transfer catalytic synthesis of α-amino acid via alkylation and nucleophilic addition of benzaldehyde amines. Tetrahedron 1988, 44, 5343-5353.
23. Oppolzer, W. Camphor as a natural source of chirality in asymmetric synthesis. Pure Appl. Chem. 1990, 62, 1241-1250.
24. Josien, H.; Martin, A.; Chassaing, G. Asymmetric synthesis of L-pyrenylalanine and L-9-fluorenylglycine via room-temperature alkylations of a sultam-derived glycine imine. Tetrahedron Lett. 1991, 32, 6547-6550.
25. Bischoff, L.; David, C.; Martin, L.; Meudal, H.; Roques, B. P.; Fournié-Zaluski, M. C. 2,4-dinitrophenyl-4-methoxybenzyl disulfide: A new efficient reagent for the electrophilic sulfenylation of β-amino ester enolates. J. Org. Chem. 1997, 62, 4848-4850.
26. Swaminathan S.; Eswaramoorthy S. Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat. Struct. Biol. 2000, 7, 693-9.
27. Schmidt, J. J.; Bostian, K. A. Endoproteinase activity of type A botulinum neurotoxin: substrate requirements and activation by serum albumin. J. Protein Chem. 1997, 16, 19-26.
28. Piquilloud, Y.; Reinharz, A. Roth, M. Studies of the angiotensin converting enzyme with different substrates. Biochim. Biophys. Acta 1970, 206, 136-142.
29. Luciani, N.; de Rocquigny, H.; Turcaud, S.; Romieu, A.; Roques, B. P. Highly sensitive and selective fluorescence assays for rapid screening of endothelin-converting enzyme inhibitors. Biochem. J. 2001, 356, 813-819.
30. Goudreau, N.; Guis, C.; Soleilhac, J. M.; Roques, B. P. Dns-Gly-(p-NO2)Phe-beta Ala, a specific fluorogenic substrate for neutral endopeptidase 24.11. Anal. Biochem. 1994, 219, 87-95.
31. Klein, A. W. Treatment of wrinkles with Botox. In Hyperhydrosis and botulinum toxin in dermatology; Kreyden, O. P.; Böni, R.; Burg, G., Eds.; Karger, Basel, 2002; pp 188-221.
32. Lew, M. F.; Brashear, A.; Factor, S. The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystonia: summary of three controlled clinical trials. Neurology 2000, 55, S29-S35.
33. Adler, M.; Dinterman, R. E.; Wannemacher, R. W. Protection by the heavy metal chelator N,N,N′,N′-tetrakis (2-pyridylmethyl)ethylenediamine (TPEN) against the lethal action of botulinum neurotoxin A and B. Toxicon 1997, 35, 1089-1100.
34. Foran, P.; Shone, C. C.; Dolly, J. O. Differences in the protease activities of tetanus and botulinum B toxins revealed by the cleavage of vesicle-associated membrane protein and various sized fragments. Biochemistry 1994, 33, 15365-15374.
35. Keller, J. E.; Nowakowski, J. L.; Filbert, M. G.; Adler, M. Rapid microplate assay for monitoring botulinum neurotoxin B catalytic activity. J. Appl. Toxicol. 1999, 19 Suppl 1, S13-17.
36. Adler, M.; Nicholson, J. D.; Cornille, F.; Hackley, B. E., Jr. Efficacy of a novel metalloprotease inhibitor on botulinum neurotoxin B activity [published erratum appears in FEBS Lett. 1998, 437, 164]. FEBS Lett. 1998, 429, 234-238.
37. Adler, M.; Nicholson, J. D.; Cornille, F.; Hackley, B. E., Jr. Efficacy of a novel metalloprotease inhibitor on botulinum neurotoxin B activity [published erratum appears in FEBS Lett. 1998, 437, 164]. FEBS Lett. 1998, 429, 234-238.
38. de Paiva, A.; Ashton, A. C.; Foran, P.; Schiavo, G.; Montecucco, C.; Dolly, J. O. Botulinum A like type B and tetanus toxins fulfils criteria for being a zinc-dependent protease. J. Neurochem. 1993, 61, 2338-2341.
39. Shone, C. C.; Quinn, C. P.; Wait, R.; Hallis, B.; Fooks, S. G.; Hambleton, P. Proteolytic cleavage of synthetic fragments of vesicle-associated membrane protein, isoform-2 by botulinum type B neurotoxin. Eur. J. Biochem. 1993, 217, 965-971.
40. Adler, M.; Nicholson, J. D.; Starks, D. F.; Kane, C. T.; Cornille, F.; Hackley, B. E. Jr. Evaluation of phosphoramidon and three synthetic phosphonates for inhibition of botulinum neurotoxin B catalytic activity. J. Appl. Toxicol. 1999, 19 Suppl. 1, S5-S11.
41. Hanson, M. A.; Oost, T. K.; Sukonpan, C.; Rich, D. H.; Stevens, R. C. Structural basis fof BABIM inhibition of botulinum neurotoxin type B protease. J. Am. Chem. Soc. 2000, 122, 11268-11269.
42. Garcia, G. E.; Moorad, D. R.; Gordon, R. K. Buforin I, a natural peptide, inhibits botulinum neurotoxin B activity in vitro. J. Appl. Toxicol. 1999, 19 Suppl. 1, S19-22.
43. Shone, C. C.; Roberts, A. K. Peptide substrate specificity and properties of the zinc-endopeptidase activity of botulinum type B neurotoxin. Eur. J. Biochem. 1994, 225, 263-270.
44. Roques, B. P. Novel approaches to targeting neuropeptide systems. Trends Pharmacol. Sci. 2000, 21, 475-483.
45. Roques, B. P., Anne, C. Turcaud, S., Fournié-Zaluski, M. C., Inhibiteurs de la toxine botuligne de type B, Patent Fr 0104895; PCT Fr 0201258, 2001.
46. Eswaramoorthy, S.; Kumaran, D.; Swaminathan, S. A novel mechanism for clostridium botulinum neurotoxin inhibition. Biochemistry 2002, 41, 9795-9802.